Management of Bile Acid Sequestrants

Introduction to Bile Acid Sequestrants

Bile acid sequestrants, such as cholestyramine, bind bile acids in the intestinal lumen, forming an insoluble complex, which depletes the liver of bile acids and increases bile acid production from cholesterol, contributing to its therapeutic effect of reducing LDL cholesterol levels by 18-25% at standard doses, as recommended by the American Heart Association 1, 2, 3, 4
Cholestyramine depletes intracellular cholesterol pools, upregulating LDL receptor activity, leading to a reduction in LDL cholesterol levels 4

The American Gastroenterological Association recommends taking colestipol with meals to reduce gastrointestinal effects, and ensuring adequate fluid intake with each dose, considering taking 30 minutes before meals rather than with meals 5
The American Gastroenterological Association suggests monitoring lipid levels to ensure therapeutic effect is maintained if dose is reduced, and considering monitoring fat-soluble vitamin levels with long-term use 2
Starting dose of cholestyramine: 2-4 g/day, titrate gradually based on response (maximum: 24 g/day), with gradual titration recommended to minimize side effects, according to the American Gastroenterological Association 2
Starting dose of colestipol: 1g twice daily, gradually increase by 1g every other day based on response, maximum dose: 16g/day (tablelets) or 30g/day (granules) 2, 6
Dosing of colesevelam: 625mg tablets, 3 tablets twice daily or 6 tablets once daily, or 3.75g powder packet once daily 6

Bile acid sequestrants are contraindicated in patients with triglycerides >500 mg/dL, history of hypertriglyceridemia-induced pancreatitis, bowel obstruction, or extensive ileal resection (>100 cm) or severe involvement, according to the American Gastroenterological Association and American College of Cardiology 2, 6
Patients with gastroparesis, GI motility disorders, or history of major GI tract surgery should use cholestyramine with caution 6
The American Gastroenterological Association recommends avoiding colestipol in patients with extensive ileal resection (>100 cm) 5

The American Gastroenterological Association recommends administering other medications at least 1 hour before or 4-6 hours after colestipol, and reviewing concurrent medications as colestipol may bind other drugs 2
Cholestyramine may decrease absorption of other medications, and critical medications should be administered at least 4 hours before cholestyramine, with specific medications requiring separation including cyclosporin, oral contraceptives containing ethinyl estradiol and norethindrone, olmesartan, phenytoin, sulfonylureas, thyroid replacement therapy, and warfarin 6
Other medications should be taken at least 1 hour before or 4 hours after bile acid sequestrants to avoid impeding their absorption, and schedule other medications appropriately to avoid reduced absorption 7, 6
Bile acid sequestrants are associated with gastrointestinal side effects, including nausea, vomiting, abdominal discomfort, flatulence, diarrhea, and constipation, with constipation being the most common, although colesevelam has demonstrated adverse rates similar to placebo in multiple studies 2, 6

The American Society for Clinical Oncology suggests reducing spicy foods, caffeine, and alcohol, and avoiding milk and dairy products (except yogurt and firm cheeses) 8

Triglyceride levels should be monitored closely as cholestyramine may increase triglycerides, and signs of pancreatitis should be monitored, with cholestyramine discontinued if symptoms develop 6
INR should be monitored frequently during initiation in patients on warfarin, and vitamin levels should be considered for monitoring in long-term use, as cholestyramine may cause vitamin K or fat-soluble vitamin deficiencies 6

For patients who cannot tolerate cholestyramine, colesevelam may be considered as an alternative, which has better tolerability and fewer drug interactions, though at higher cost 9
Ezetimibe is a cholesterol absorption inhibitor with 18-25% LDL reduction, and can be combined with other agents for additive effect 4
Bempedoic acid is an ATP citrate lyase inhibitor with 20-28% LDL reduction, and is a well-tolerated alternative for statin-intolerant patients 4
PCSK9 inhibitors achieve powerful LDL reduction (40-65%) and are reserved for patients requiring significant LDL reduction, particularly in high-risk patients 4, 10

Cholestyramine is generally considered safe during pregnancy and lactation, but individual risk-benefit assessment should be performed in these populations 6

The efficacy of colestipol is 10.4% LDL-C reduction as monotherapy, and 16.3-27.2% LDL-C reduction depending on dose (5-15g) 7, 6
The efficacy of colesevelam is 15% LDL-C reduction as monotherapy; additional 10-16% when combined with statins, and it is the most potent bile acid sequestrant with 4-6 times stronger binding affinity to bile acids 2, 6
The International Atherosclerosis Society and American College of Cardiology recognize bile acid sequestrants as effective alternatives for LDL reduction, with good evidence for approximately 20% CVD risk reduction in primary prevention 4, 10